TY1A-NL2 Antibody

What is the target specificity of TY1A-NL2 Antibody in neurological tissue samples?

TY1A-NL2 Antibody targets specific domains of neuroligin 2 (NLGN2), a postsynaptic cell adhesion molecule critical for synaptic development and function. NLGN2 is expressed in neurons throughout the brain and has been detected in pancreatic β cells where it facilitates insulin secretion . When applying this antibody in neurological tissue, researchers should note that NLGN2 labeling appears prominently in the cell bodies of dorsal root ganglion (DRG) neurons and can be detected in neuronal outlines in structures such as the reticular thalamic nucleus . Proper understanding of this specificity is essential for accurate interpretation of immunohistochemical results in neurological research applications.

What detection systems are most compatible with TY1A-NL2 Antibody for visualizing low-abundance proteins?

For low-abundance protein detection using TY1A-NL2 Antibody, tyramide signal amplification (TSA) has demonstrated superior sensitivity compared to conventional methods. TSA is particularly effective because it utilizes HRP-activated tyramide that covalently binds to electron-rich amino acids at the immunoreaction site, creating a stable signal resistant to subsequent processing steps . When combined with HRP polymer-conjugated secondary antibodies, this system introduces a large number of peroxidase molecules that remarkably enhance detection sensitivity . This hybrid approach allows for the visualization of proteins that are present in small or barely detectable amounts, which is particularly valuable when working with sparsely expressed proteins in the nervous system. The implementation of this detection system also simplifies staining procedures and reduces costs by permitting further dilution of expensive primary antibodies .

How does TY1A-NL2 Antibody performance compare in clinical trial applications versus standard laboratory research?

In clinical applications, anti-TL1A monoclonal antibodies like tulisokibart have shown significant efficacy in controlled trials. For instance, in a Phase 2 trial for ulcerative colitis treatment, patients receiving tulisokibart demonstrated substantially higher clinical remission rates (26%) compared to placebo (1%), with a difference of 25 percentage points (95% CI, 14 to 37; P<0.001) . This clinical performance validates the specificity and efficacy of anti-TL1A antibodies in human subjects.

In laboratory research settings, anti-NLGN2 antibodies have demonstrated high specificity across multiple experimental platforms, including western blot analysis of rat and mouse brain membrane samples and rat PC12 pheochromocytoma cells . The antibody effectively detects NLGN2 in both fixed tissue samples and living cells, making it versatile for various research applications . These differences in performance metrics between clinical and laboratory settings highlight the importance of context-specific validation when transitioning research tools to therapeutic applications.

What are the advantages and limitations of combining TY1A-NL2 Antibody with RNAScope for dual protein-RNA detection?

Combining TY1A-NL2 Antibody immunodetection with RNAScope in situ hybridization offers significant advantages for comprehensive protein-RNA expression analysis. This dual approach allows simultaneous visualization of both protein localization and mRNA expression patterns, providing insight into post-transcriptional regulation mechanisms . When properly optimized, these techniques are highly compatible with formaldehyde-fixed paraffin-embedded tissue, preserving delicate morphological characteristics while enabling detection of sparsely expressed genes .

How can researchers address epitope masking when using TY1A-NL2 Antibody in fixed tissue samples?

Epitope masking is a significant challenge when applying TY1A-NL2 Antibody to fixed tissue samples, particularly in formaldehyde-fixed paraffin-embedded tissues. To address this issue, researchers should implement optimized antigen retrieval methods. Heat-induced epitope retrieval using 10 mM citrate buffer (pH 6.0) has proven effective for unmasking antigens while preserving tyramide-amplified signals from previous staining rounds .

For complex multiple immunolabeling protocols, implementing a sequential approach is recommended. This involves completing one round of immunolabeling with tyramide signal amplification, followed by antibody elution through heat treatment (10 minutes of microwave treatment in citrate buffer), then proceeding with subsequent rounds of staining . This strategy effectively removes bound primary and secondary antibodies while preserving the covalently bound tyramide signal. The heat treatment using citrate buffer does not significantly reduce fluorescent signal from the first round of staining, confirming that HRP-activated tyramide binds covalently and efficiently to proteins at the immunoreaction site, making it resistant to the citrate treatment .

What protocol modifications are necessary when implementing multiple immunolabeling with TY1A-NL2 Antibody?

When implementing multiple immunolabeling protocols with TY1A-NL2 Antibody, several critical modifications are necessary for optimal results. First, researchers should utilize a combined approach involving antibody elution between staining rounds, HRP polymer-conjugated secondary antibodies, and tyramide signal amplification . This integrated strategy overcomes the traditional limitations of multiple immunofluorescence labeling, particularly when using primary antibodies from the same host species.

A recommended protocol includes:

• Initial immunostaining with primary antibody followed by HRP polymer-conjugated secondary antibody (e.g., ImmPRESS™ HRP IgG Polymer Detection Kit)

• Signal detection using diluted fluorescein tyramide (1:500 in amplification buffer rather than the manufacturer-recommended 1:50)

• Elution of bound primary and secondary antibodies by heat treatment in 10 mM citrate buffer (pH 6.0) for 10 minutes in a microwave

• Proceeding with subsequent rounds of immunostaining with different primary antibodies

This approach provides bright antigen labeling that significantly surpasses results obtained using fluorescently tagged secondary antibodies alone. The HRP polymer-conjugated system introduces numerous peroxidase molecules, enhancing detection sensitivity while simplifying the staining procedure compared to traditional avidin-biotin complex methods .

How should researchers validate TY1A-NL2 Antibody specificity for new experimental contexts?

Rigorous validation of TY1A-NL2 Antibody specificity is critical when applying this reagent to new experimental contexts. A comprehensive validation approach should include multiple complementary techniques:

• Western blot analysis with appropriate controls: Testing the antibody against target tissue (e.g., rat and mouse brain membrane samples) alongside negative control samples. Include antibody preincubation with specific blocking peptides (e.g., Neuroligin 2 extracellular blocking peptide) to confirm binding specificity .

• Immunohistochemical validation: Perform parallel staining of tissues known to express the target (e.g., dorsal root ganglion neurons for NLGN2) with appropriate controls. Include nuclear counterstaining (e.g., DAPI) to provide context for the observed expression patterns .

• Live cell surface detection: For antibodies targeting extracellular epitopes, validate specificity by staining intact living cells (e.g., PC12 cells for NLGN2) without permeabilization to confirm accessibility of the epitope under native conditions .

• Genetic validation: Where possible, testing antibody reactivity in tissues from knockout or knockdown models provides the most stringent validation of specificity.

This multi-faceted approach ensures that observed signals truly represent the intended target protein across different experimental systems and conditions.

What statistical considerations are important when analyzing results from antibody-based genetic response prediction models?

When analyzing results from antibody-based genetic response prediction models, several statistical considerations are crucial for proper interpretation. In clinical research with tulisokibart, a genetic-based diagnostic test was designed to identify patients with an increased likelihood of response . Analysis of such prediction models requires careful attention to several statistical factors:

• Cohort stratification: When designing studies with genetic predictors, proper stratification of cohorts is essential. For example, in the tulisokibart trial, patients were divided into Cohort 1 (patients regardless of genetic test status) and Cohort 2 (only patients with a positive genetic test for likelihood of response) .

• Treatment effect size calculation: Calculate the difference in response rates between treatment and placebo groups with 95% confidence intervals. In the case of tulisokibart, among patients with a positive test for likelihood of response, clinical remission occurred in 32% of treated patients versus 11% with placebo (difference: 21 percentage points; 95% CI: 2 to 38; P = 0.02) .

• Combined analysis considerations: When combining data from different cohorts (as in the tulisokibart study where patients with positive test results from Cohorts 1 and 2 were combined), researchers must ensure this was prespecified in the analysis plan to avoid post-hoc selection bias .

• Sample size adequacy: Ensure sufficient statistical power to detect meaningful differences, particularly in stratified analyses. The tulisokibart study had 135 patients in Cohort 1 and 43 in Cohort 2, with 75 patients with a positive test for likelihood of response across both cohorts .